Metoclopramide and Ondansetron Infusion for Hyperemesis Gravidarum

Last Review Date: April 13, 2018
Number: MG.MM.ME.c

Medical Guideline Disclaimer
Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions
Hyperemesis gravidarum (HG) — a severe form of nausea and vomiting in pregnancy, generally described as unrelenting and excessive, which prevents adequate food and fluid intake. HG usually starts before 9 weeks of gestation and may resolve by 22 weeks with the most refractory cases lasting until delivery.
Severe and/or inadequately treated HG is typically associated with:

1. Loss of weight ≥ 5% of pre-pregnancy body weight (usually > 10%)
2. Dehydration (may be evidenced by diagnostic laboratory studies; e.g., urinalysis for ketones and specific gravity, serum electrolytes, liver enzymes and bilirubin, amylase/lipase, TSH, free thyroxine, urine culture, calcium level and hematocrit, etc.)
3. Nutritional deficiencies
4. Difficulty with daily activities

Guideline
Members diagnosed with HG (documentation must support 1–4 above) may be eligible for coverage of home infusion with metoclopramide or odansetron when a trial of medications, regardless of drug class, fails to relieve symptoms; either:

1. Any 2 oral medications (includes sublingual)
2. Any oral medication and at least 1 rectal medication

The following pharmacologic management guide for nausea, vomiting and dehydration is recommended.

Note: drugs and classes listed not meant to be all-inclusive; dosing protocols not included, as accepted variances exist within the medical community.

1st. Monotherapy — Pyridoxine (vitamin B6) (ginger capsules may also be added)
2nd. Add doxylamine (antihistamine) (ginger capsules may also be added)

3rd. Add Metoclopramide (prokinetic) orally
   The following may also be added: Promethazine (antidopaminergic), orally or rectally; or,
   dimenhydrinate (antihistamine), orally or rectally

4th. Intravenous fluid replacement with thiamine followed by intravenous multivitamins with the addition
   of dimenhydrinate, metoclopramide or promethazine infusion

5th. Ondansetron 4–8mg orally or IV every 8 hours can be used (see Limitations/Exclusions cautionary
    information on dosing)

6th. Methylprednisolone (corticosteroid), orally or intravenously, for 3 days with tapering to lowest
    effective dose over 2 weeks or ondansetron infusion¹ (serotonin antagonist). Methylprednisolone
    should not be administered before 10 weeks of gestation

Limitations/Exclusions

Ondansetron should not be given IV in doses greater than 16 mg to avoid the potential cardiac risk associated
with prolonged QT interval. Antihistamines should be avoided in women taking ondansetron or other medications
that prolong the Q-T interval.

Electrolyte and electrocardiogram monitoring are recommended for members being treated with ondansetron
who have risk factors for arrhythmia, including family or personal history of prolonged QT interval, heart failure,
hypokalemia, hypomagnesemia, and use of other medications that lead to prolongation of the QT interval.

Revision History

4/21/2017 — moved Odansetron from 6th to 5th in the treatment paradigm and added administration protocol
3/11/2016 — removed time-frame prerequisite prior to IV fluid replacement

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99601</td>
<td>Home infusion/specialty drug administration, per visit (up to 2 hours)</td>
</tr>
<tr>
<td>99602</td>
<td>Home infusion/specialty drug administration, per visit (up to 2 hours); each additional hour</td>
</tr>
<tr>
<td>J2405</td>
<td>Injection, ondansetron HCl, per 1 mg</td>
</tr>
<tr>
<td>J2765</td>
<td>Injection, metoclopramide HCl, up to 10 mg</td>
</tr>
<tr>
<td>S9351</td>
<td>Home infusion therapy, continuous or intermittent antiemetic infusion therapy; administrative</td>
</tr>
<tr>
<td>S9379</td>
<td>Home infusion therapy, infusion therapy, not otherwise classified; administrative services,</td>
</tr>
</tbody>
</table>

Applicable ICD-10 Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>O21.0</td>
<td>Mild hyperemesis gravidarum</td>
</tr>
<tr>
<td>O21.1</td>
<td>Hyperemesis gravidarum with metabolic disturbance</td>
</tr>
</tbody>
</table>

¹ Ondansetron safety has not been established, particularly in the first trimester of pregnancy (pregnancy category B).
References

Specialty-matched clinical peer review.